文献速递其他结缔组织病

多种血清生物标志物与系统性硬化症死亡及间质性肺病进展相关

Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

基于澳大利亚硬皮病队列研究,分析407例系统性硬化症患者中27种血清生物标志物与死亡及间质性肺病进展的关联。中位随访6.31年,16种标志物与死亡增加相关,VCAM-1关联最强(HR 3.55);CXCL4、MMP-1和ET-1与1年时间质性肺病进展相关。

要点

  • VCAM-1高水平与死亡关联最强(HR 3.55,95%CI 2.37-5.33,P<0.001)。
  • SP-D、E-selectin、IL-6、MMP-3和ET-1的死亡HR均大于2。
  • CXCL4、MMP-1和ET-1与1年时间质性肺病进展相关。

核心结论

  • 多种生物标志物,尤其是VCAM-1、E-selectin、SP-D和CXCL4,在既定风险因素之外提供预后价值。

研究设计与样本

  • 从澳大利亚硬皮病队列研究中识别具有基线12个月内血清、高分辨率CT和肺功能数据的参与者,基线为血清采集时间。
  • 共分析28种预设血清生物标志物中的27种,采用单因素和多因素分析探讨生物标志物与死亡及间质性肺病进展的关联,包括在疾病亚组内及与既定不良预后风险因素联合分析。

主要发现

  • 共识别407例参与者,其中252例(61.9%)患有系统性硬化症相关间质性肺病。
  • 生物标志物检测后中位随访6.31年(四分位距3.11-9.22年)。
  • 16种生物标志物与死亡增加相关,VCAM-1高水平与死亡的关联最强(HR 3.55,95%CI 2.37-5.33,P<0.001)。
  • 另有5种生物标志物的HR大于2:SP-D(2.28,95%CI 1.57-3.31,P<0.001)、E-selectin(2.19,95%CI 1.53-3.14,P<0.001)、IL-6(2.15,95%CI 1.50-3.09,P<0.001)、MMP-3(2.05,95%CI 1.42-2.95,P<0.001)和ET-1(2.03,95%CI 1.40-2.92,P<0.001)。
  • 调整性别、年龄和基线用力肺活量(FVC%预计值)后,11种生物标志物与死亡独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the prognostic utility of 28 serum biomarkers in systemic sclerosis (SSc), SSc-associated interstitial lung disease (SSc-ILD) and clinically relevant disease subgroups. METHODS: Participants with sera, high-resolution CT and lung function within 12 months of baseline were identified from the Australian Scleroderma Cohort Study. Baseline was the time of serum collection. Twenty-seven of the prespecified 28 serum biomarkers were analysed and biomarker associations with mortality and ILD progression were investigated in univariable and multivariable analyses, including within disease subgroups and combined with established risk factors for poorer prognosis in SSc. RESULTS: A total of 407 participants were identified, 252 (61.9%) with SSc-ILD. The median (interquartile range) follow-up after biomarker measurement was 6.31 (3.11-9.22) years. Sixteen biomarkers were associated with increased mortality. High levels of VCAM-1 were most strongly associated with mortality [hazard ratio (HR) 3.55; 95% CI 2.37-5.33; P < 0.001]. Five additional biomarkers had an HR >2: SP-D (2.28, 1.57-3.31; P < 0.001), E-selectin (2.19, 1.53-3.14; P < 0.001), IL-6 (2.15, 1.50-3.09; P < 0.001), MMP-3 (2.05, 1.42-2.95; P < 0.001) and ET-1 (2.03, 1.40-2.92; P < 0.001). Eleven biomarkers were independently associated with mortality following adjustment for sex, age and baseline forced vital capacity (FVC%predicted). Three biomarkers were associated with ILD progression at 1-year follow-up: CXCL4 (odds ratio 2.67, 1.46-4.88; P = 0.001), MMP-1 (2.56, 1.43-4.59; P = 0.002) and ET-1 (2.18, 1.24-3.83; P = 0.007). CONCLUSION: Multiple biomarkers, especially VCAM-1, E-selectin, SP-D and CXCL4, provide prognostic utility beyond that of established risk factors for patients with SSc.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Parker MJS, Jee AS, Hansen D, et al. Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis. Rheumatology (Oxford). 2024. PMID: 38366632. doi:10.1093/rheumatology/keae110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。